drugset
drugset / Trial / NCT04439838

A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated

NCT04439838 ↗

Phase 1 Completed 64 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1595043 in healthy male subjects following oral administration of single rising doses.

Timeline

Start
2020-08-13
Primary completion
2021-03-19
Completion
2021-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1595043 Unknown 1 mg Oral
Subject BI 1595043 Unknown 3 mg Oral
Subject BI 1595043 Unknown 6 mg Oral
Subject BI 1595043 Unknown 12 mg Oral
Subject BI 1595043 Unknown 25 mg Oral
Subject BI 1595043 Unknown 50 mg Oral
Subject BI 1595043 Unknown 90 mg Oral
Subject BI 1595043 Unknown 160 mg Oral

Indications

No indication recorded.